Merck & Co. MRK Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 302.5%-2.5pp | 305%-1.5pp | 306.5%+1.4pp | 305.2%+1.3pp | 303.8%+2.1pp | |
| Net margin | 97.1%-13.7pp | 110.8%+1.4pp | 109.4%— | —— | —— | |
| Returns | ||||||
| Return on equity | 130.8%-20.3pp | 151.2%-3.9pp | 155.1%— | —— | —— | |
| Return on invested capital | 80.6%-12.8pp | 93.4%-1.9pp | 95.3%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 2.1×0.0× | 2.2×-0.1× | 2.2×0.0× | 2.3×0.0× | 2.3×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.9×-0.1× | 6×+0.2× | 5.9×+0.3× | 5.6×0.0× | 5.6×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 3.7×+0.3× | 3.3×+0.1× | 3.2×-0.1× | 3.3×-0.2× | 3.5×-0.2× | |
| Net debt / EBITDA | 6.9×+1.7× | 5.2×+0.3× | 4.9×— | —— | —— | |
| Valuation | ||||||
| Market capitalization | $969.99B+7.9% | $899.32B+1.1% | $889.71B-8.1% | $967.83B-10.4% | $1.08T-9.1% | |
| Price / earnings | 70.9×+20.3× | 50.6×-0.4× | 51×— | —— | —— | |
| Price / sales | 15×+1.0× | 14×+0.1× | 13.9×-1.3× | 15.2×-1.8× | 17×-1.9× | |
| Price / book | 19.6×+1.8× | 17.8×-0.5× | 18.3×-2.4× | 20.7×-3.1× | 23.8×-3.6× | |
| EV / EBITDA | 56.2×+11.7× | 44.5×-0.2× | 44.7×— | —— | —— | |
| Dividend yield | 13.7%-0.7pp | 14.5%0.0pp | 14.5%+1.2pp | 13.3%+1.5pp | 11.7%+1.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Merck & Co.'s ratios come from?
- Every ratio is computed from Merck & Co.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
